Merck halts more trials of HIV candidate islatravir

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy.

Data sets up 2021 filings for Gilead's twice-a-year HIV drug...

Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course fo

Gilead's Descovy approved in HIV prophylaxis

The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compa

Gilead will challenge US government patent on PrEP drug Truv...

Gilead’s Descovy gets FDA panel OK for PrEP, but not for wom...

FDA reviewer backs Gilead’s Descovy for PrEP, but not in wom...